Debra Research takes 12.8% stake in Healome Therapeutics
Published
Debra Research GmbH is the largest new holder in Healome Therapeutics, an eye-drop technology firm, with Ordinary A shares.
SFC Nominees Limited A/C EV entered the register with an 8.9% holding in Ordinary A shares.
Empirical Ventures BBI Nominees Limited entered with 3.8% in Ordinary A shares.
Cure EB entered with a 2.6% Ordinary A holding.
SFC BBI Nominees Ltd entered with 1.8% in Ordinary A shares.
The register also records an increase for SFC Nominees Limited A/C SFCAF, while the overall share count rose. The changes span a multi-year period from 10 January 2022 to 10 January 2026, with the statement filed on 24 January 2026.
Shareholder data
Source: Companies House confirmation statement (CS01) — period to , filed .
Changes in this confirmation statement
| Type | Shareholder | Shares | Change | Share classes |
|---|---|---|---|---|
| Exited | SFC NOMINEES LIMITED | 378,947 | — | ORDINARY A 378,947 |
| New shareholder | DEBRA RESEARCH GMBH | 1,660,607 | — | ORDINARY A 1,660,607 |
| New shareholder | SFC NOMINEES LIMITED A/C EV | 1,162,425 | — | ORDINARY A 1,162,425 |
| New shareholder | SFC NOMINEES LIMITED A/C SFCAF | 810,704 | — | ORDINARY A 810,704 |
| New shareholder | EMPIRICAL VENTURES BBI NOMINEES LIMITED | 498,182 | — | ORDINARY A 498,182 |
| New shareholder | SFC BBI NOMINEES LTD | 232,485 | — | ORDINARY A 232,485 |
Current shareholders (7)
| Shareholder | Total shares | Share classes |
|---|---|---|
| THE UNIVERSITY OF BIRMINGHAM | 2,736,842 | ORDINARY 1,768,421 DEFERRED 968,421 |
| DEBRA RESEARCH GMBH | 1,660,607 | ORDINARY A 1,660,607 |
| SFC NOMINEES LIMITED A/C EV | 1,162,425 | ORDINARY A 1,162,425 |
| KCP NOMINEES LTD | 884,211 | ORDINARY A 884,211 |
| SFC NOMINEES LIMITED A/C SFCAF | 810,704 | ORDINARY A 810,704 |
| EMPIRICAL VENTURES BBI NOMINEES LIMITED | 498,182 | ORDINARY A 498,182 |
| SFC BBI NOMINEES LTD | 232,485 | ORDINARY A 232,485 |
Contact the editorial team at editorial@fundingspotter.com